glp-1 telehealth crackdown news Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight FDA issued 30 warning letters

On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active pharmaceutical ingredients (APIs) from manufacturers not included on its newly established Green List.[1] This action follows FDAs September 5 th announcement of the Green List initiative to curb illegal imports of semaglutide, tirzepatide, and other corresponding APIs.[2] Together, the Green List and Import Alert form FDAs most aggressive enforcement measures to date against GLP-1 imports

The RR for the occurrence of respiratory disease in patients receiving Lixisenatide was 0.83 (95% CI 0.621.12, p = 0.22)

If you and your doctor do decide to taper you off your medication, continuing lifestyle changes can make a huge difference on your outcomes

Black or tarry stool, visible blood in the stool, vomiting blood, severe abdominal pain, unexplained weight loss, persistent fever, anemia, or progressive swallowing difficulty should be evaluated appropriately